These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 28571533

  • 1. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ, Zhou H, Lu Q.
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The discovery and maturation of peptide biologics targeting the small G-protein Cdc42: A bioblockade for Ras-driven signaling.
    Tetley GJN, Murphy NP, Bonetto S, Ivanova-Berndt G, Revell J, Mott HR, Cooley RN, Owen D.
    J Biol Chem; 2020 Feb 28; 295(9):2866-2884. PubMed ID: 31959628
    [Abstract] [Full Text] [Related]

  • 4. Progress in the therapeutic inhibition of Cdc42 signalling.
    Murphy NP, Mott HR, Owen D.
    Biochem Soc Trans; 2021 Jun 30; 49(3):1443-1456. PubMed ID: 34100887
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes.
    Teramoto H, Malek RL, Behbahani B, Castellone MD, Lee NH, Gutkind JS.
    Oncogene; 2003 May 01; 22(17):2689-97. PubMed ID: 12730683
    [Abstract] [Full Text] [Related]

  • 9. Cdc42 in oncogenic transformation, invasion, and tumorigenesis.
    Stengel K, Zheng Y.
    Cell Signal; 2011 Sep 01; 23(9):1415-23. PubMed ID: 21515363
    [Abstract] [Full Text] [Related]

  • 10. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E, Spinelli M, Vanoni M.
    Expert Opin Ther Pat; 2012 Nov 01; 22(11):1263-87. PubMed ID: 23009088
    [Abstract] [Full Text] [Related]

  • 11. Ras proteins as therapeutic targets.
    Chakraborty A, Linnane E, Ross S.
    Biochem Soc Trans; 2018 Oct 19; 46(5):1303-1311. PubMed ID: 30154091
    [Abstract] [Full Text] [Related]

  • 12. Targeting Rac and Cdc42 GTPases in Cancer.
    Maldonado MDM, Dharmawardhane S.
    Cancer Res; 2018 Jun 15; 78(12):3101-3111. PubMed ID: 29858187
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.
    Aguilar BJ, Zhao Y, Zhou H, Huo S, Chen YH, Lu Q.
    Cancer Biol Ther; 2019 Jun 15; 20(6):740-749. PubMed ID: 30849276
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E, Solit DB.
    J Pathol; 2011 Jan 15; 223(2):219-29. PubMed ID: 21125676
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rho GTPases: promising cellular targets for novel anticancer drugs.
    Fritz G, Kaina B.
    Curr Cancer Drug Targets; 2006 Feb 15; 6(1):1-14. PubMed ID: 16475973
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J, Wang J, Chang S, Liu M, Pang X.
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan 15; 48(1):17-26. PubMed ID: 26487443
    [Abstract] [Full Text] [Related]

  • 20. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
    Yan C, Theodorescu D.
    Pharmacol Rev; 2018 Jan 15; 70(1):1-11. PubMed ID: 29196555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.